|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.38 USD | -4.63% |
|
-1.50% | -1.07% |
| 03-24 | Neurogene Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| 03-03 | Neurogene announces inducement grants under Nasdaq Listing Rule 5635(c)(4) | RE |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
Biological Products | |||||
Biotechnology (Startups) | - | - | - | 925K | - |
Total Assets | 101M | 109M | 223M | 336M | 289M |
Interest Expense | - | -2K | -12K | -12K | -5K |
CAPEX | -18.37M | -2.23M | -321K | -808K | -1.18M |
EBT | -50.52M | -55.19M | -36.32M | -75.14M | -90.35M |
D&A | 947K | 3.2M | 3.3M | 3.25M | 3.09M |
Operating Income | -50.53M | -56.52M | -55.58M | -82.6M | -103M |
Net Income | -50.52M | -55.19M | -36.32M | -75.14M | -90.35M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
United States | - | - | - | 925K | - |
Total Assets | 101M | 109M | 223M | 336M | 289M |
Interest Expense | - | -2K | -12K | -12K | -5K |
D&A | 947K | 3.2M | 3.3M | 3.25M | 3.09M |
CAPEX | -18.37M | -2.23M | -321K | -808K | -1.18M |
Net Income | -50.52M | -55.19M | -36.32M | -75.14M | -90.35M |
EBT | -50.52M | -55.19M | -36.32M | -75.14M | -90.35M |
Operating Income | -50.53M | -56.52M | -55.58M | -82.6M | -103M |
- Stock Market
- Equities
- NGNE Stock
- Financials Neurogene Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition